INTRODUCTION {#S1}
============

Despite decades of research and advances in clinical management, sepsis and septic shock remain the leading causes of death among intensive care unit patients. The complex interaction between the infecting pathogen and the host immune system in sepsis involves multiple distinct pathways. Among the most frequently isolated pathogens in sepsis patients are Gram-negative bacteria, such as *Escherichia coli*. Pattern-recognition receptors (e.g., toll-like receptors) are the central components of the innate immune system that recognize exogenous pathogen-associated molecular patterns (PAMPs) and endogenous damage-associated molecular patterns (DAMPs) and trigger both adaptive and maladaptive aspects of the immune response during severe infection ([@R15]). The maladaptive host response is generally characterized by two distinct stages: excessive inflammation at early stage and sustained immune suppression at late stage ([@R45]). In particular, immune suppression from T cell dysfunction or apoptosis is frequently associated with sepsis-related deaths in patients ([@R3]; [@R38]). In fact, increasing T cell viability or function using interleukin (IL)-7 has been shown to protect against septic lethality in experimental and clinical settings ([@R44]; [@R46]).

Circadian rhythms are driven by the circadian clock, which consists of interlocked transcriptional-translational feedback loops. During the daytime, the transcription factors circadian locomotor output cycles kaput (CLOCK) and brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1 (BMAL1) heterodimerize and bind to E-box promoter elements to drive the gene expression of *Period* (*Per1-3*) and *Cryptochrome* (*Cry1/2*). PER/CRY protein complexes reside in the cytoplasm throughout the day and later relocate into the nucleus, where they inhibit the activity of the CLOCK-BMAL1 complex. Disruption of the circadian clock has been linked to various disorders, including metabolic, inflammatory, and immunological diseases ([@R2]; [@R7]).

In this study, we provide evidence that BMAL1 plays a role in preventing the development of a sepsis phenotype during severe infection through counter-regulating programmed cell death 1 ligand 1 (PD-L1), an immune checkpoint protein. Pyruvate kinase M2 (PKM2) upregulation was required for lactate production and PD-L1 expression in *Bmal1*-deficient macrophages. Consequently, conditional deletion of *Bmal1* in myeloid cells accelerated death in polymicrobial sepsis, a phenotype that was reversed with anti-PD-L1-neutralizing antibody or recombinant IL-7 protein or deletion of *Pkm2*. These findings reveal a direct link between the circadian clock, metabolism, and immune suppression in the pathophysiology of sepsis.

RESULTS {#S2}
=======

Altered Circadian and Sepsis Phenotype in *Bmal1^Mye−/−^* Mice {#S3}
--------------------------------------------------------------

Myeloid cells, including monocytes and macrophages, are key effectors and regulators of inflammation and the innate immune response. To evaluate the role of the core clock gene *Bmal1 in vivo*, we generated myeloid cell-specific *Bmal1*-knockout mice (termed *Bmal1^Mye−/−^* mice) by crossing *Bmal1* ^*flox/flox*^ and *LysM-Cre*. As expected, the protein expression of BMAL1 was diminished in peritoneal macrophages (PMs) from *Bmal1^Mye−/−^* mice, but not from control *Bmal1*^*flox/flox*^ mice ([Figure 1A](#F1){ref-type="fig"}). BMAL1 protein levels in other tissues, such as the brain and liver, remained unchanged, confirming the myeloid-cell-specific ablation of *Bmal1* in mice ([Figure 1A](#F1){ref-type="fig"}).

As BMAL1 is a core component of the circadian clock, we sought to determine whether targeted ablation of *Bmal1* in myeloid cells affects the circadian oscillator in macrophages. Although mRNA expression of *Bmal1*, *Per1*, *Per2*, and *Per3* in PMs was abolished in *Bmal1^Mye−/−^* mice ([Figure 1B](#F1){ref-type="fig"}), their circadian expression in the liver tissue remained unaffected ([Figure 1C](#F1){ref-type="fig"}). Thus, the myeloid-cell-specific ablation of *Bmal1* affects circadian gene expression only within macrophages but does not influence the function of other tissues ([@R8]; [@R11]).

A clinically relevant experimental model of sepsis is induced by a surgical procedure termed cecal ligation and puncture (CLP), where the cecal appendage is ligated and then perforated with needles to cause fecal leakage as typically seen in gastroin-testinal perforations in humans ([@R4]). Zeitgeber time is a measure of time (hours) after the lights go on in the mouse facility. ZT0 corresponds to zeitgeber time 0 (namely, 'lights on'), whereas ZT12 corresponds to zeitgeber time 12 (namely, 'lights off'). Mice with myeloid-cell-specific ablation of *Bmal1* as well as control animals were subjected to CLP during ZT0--3 (namely, 'morning time') using needles that varied in gauge from 17G to 27G. Increasing needle thickness decreased percent survival from 90% (using a 27G needle; 'low-grade sepsis'), to 60% (using a 22G needle; 'middle-grade sepsis'), to 16.7% (using a 17G needle; "high-grade sepsis') in control mice *(Bmal1* ^*flox/flox*^ or *LysM-Cre* mice; [Figures 1D](#F1){ref-type="fig"}--[1F](#F1){ref-type="fig"}). In contrast, *Bmal1^Mye−/−^* mice had a significant increase in CLP-induced 10-day death rate across all three levels of sepsis severity ([Figures 1D](#F1){ref-type="fig"}--[1F](#F1){ref-type="fig"}). Consistent with a previous finding using a lethal endotoxemia model ([@R8]; [@R24]), control mice (*Bmal1* ^*flox/flox*^ or *LysM-Cre* mice) were less susceptible to the CLP-induced middle-grade sepsis at ZT0 versus ZT12 ([Figure 1G](#F1){ref-type="fig"}) compared to *Bmal1^Mye−/−^* mice ([Figure 1G](#F1){ref-type="fig"}). These findings highlight the importance of an intact circadian clock gene *Bmal1* in suppressing a lethal response to severe infection.

The Circadian Clock Blocks PD-L1 Expression in Activated Macrophages and Monocytes {#S4}
----------------------------------------------------------------------------------

Immune checkpoints are negative regulators of the immune system and emerge as a modulator of inflammation-associated immune suppression during sepsis ([@R9]). To establish whether the altered septic phenotype in *Bmal1^Mye−/−^* mice may be due to abnormal immune responses, we determined the expression of several immune checkpoint genes in macrophages. *Pd-l1* was significantly upregulated in PMs ([Figure 2A](#F2){ref-type="fig"}) from septic *Bmal1^Mye−/−^* mice. Other immune checkpoints, such as *Pd-l2*, cytotoxic T-lymphocyte associated protein 4 (*Ctla-4*), and T cell immunoglobulin mucin family member 3 (*Tim-3*), were not increased in *Bmal1*-deficient macrophages ([Figure 2A](#F2){ref-type="fig"}). Consistently, the protein levels of PD-L1 (but not PD-L2, CTLA-4, and TIM-3) were upregulated in PMs from septic *Bmal1^Mye−/−^* mice ([Figure 2B](#F2){ref-type="fig"}). We also analyzed the effects of *Bmal1* deletion on PD-L1 expression in bone-marrow-derived macrophages (BMDMs) following stimulation with a prototypic PAMP (e.g., lipopolysaccharide \[LPS\]) or DAMP (e.g., high mobility group box 1 \[HMGB1\]; [@R47]). The loss of *Bmal1* increased LPS- or HMGB1-induced *Pd-l1* mRNA ([Figure 2C](#F2){ref-type="fig"}) and protein ([Figure 2D](#F2){ref-type="fig"}) expression in BMDMs. Loss of *Bmal1* failed to affect the expression of PD-L2 ([Figures 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}). Similarly, the knockdown of *Bmal1* or *Clock* by two different short hairpin RNAs (shRNAs) increased LPS- or HMGB1-induced *Pd-l1* mRNA expression in a human leukemia monocytic THP1 cell line ([Figures 2E](#F2){ref-type="fig"} and [2F](#F2){ref-type="fig"}). A *Bmal1* I317D mutant exhibits a loss of affinity for CLOCK in the circadian clock ([@R16]). We observed that *Bmal1* I317D mutant similarly failed to inhibit the LPS- or HMGB1-induced *Pd-l1* mRNA expression in *Bmal1^Mye−/−^* BMDMs ([Figure 2G](#F2){ref-type="fig"}). These findings indicate that circadian clock genes selectively suppress PD-L1 expression in activated macrophages and monocytes.

Coincident with the increased *Pd-l1* expression in activated *Bmal1^Mye−/−^* macrophages ([Figure 2C](#F2){ref-type="fig"}), the LPS-induced *Pd-l1* mRNA expression was greater in wild-type PMs isolated at ZT12 versus at ZT0 ([Figure 2H](#F2){ref-type="fig"}), supporting that the circadian clock controls PD-L1 expression during lethal infection. Neutrophil activation by phorbol 12-myristate 13-acetate was not different between isolated circulating neutrophils from septic *Bmal1* ^*flox/flox*^ and *Bmal1^Mye−/−^* mice ([Figure 2I](#F2){ref-type="fig"}). It suggests that conditional knockout of *Bmal1* in macrophages controls the activation of macrophages, but not neutrophils, during sepsis.

Lactate Metabolism Contributes to PD-L1 Expression {#S5}
--------------------------------------------------

Sepsis and septic shock are associated with lactic acidosis ([@R43]), supporting a metabolic role of lactate in the regulation of immune response in sepsis. We and others have demonstrated that PKM2-mediated lactate metabolism in macrophages contributes to the inflammatory response, organ injury, and septic death ([@R16]; [@R28]; [@R48]; [@R50]; [@R51]). To investigate whether PKM2 is responsible for the increased risk of sepsis lethality in *Bmal1^Mye−/−^* mice, we generated myeloid-cell-specific *Bmal1* and *Pkm2* double knockout mice (*Bmal1^Mye−/−^;Pkm2^Mye−/−^* mice). As expected, the protein expression of both BMAL1 and PKM2 were absent in PMs from *Bmal1^Mye−/−^;Pkm2^Mye−/−^* mice ([Figure 3A](#F3){ref-type="fig"}). The loss of *Pkm2* did not alter the expression of *Bmal1, Per1*, and *Per2* mRNA in PMs isolated from *Bmal1^Mye−/−^;Pkm2^Mye−/−^* mice compared to *Bmal1^Mye−/−^* mice ([Figure 3B](#F3){ref-type="fig"}). However, the absence of *Pkm2* increased survival ([Figure 3C](#F3){ref-type="fig"}), reduced serum lactate levels ([Figure 3D](#F3){ref-type="fig"}), and blocked *Pd-l1* mRNA expression in PMs ([Figure 3E](#F3){ref-type="fig"}) in septic *Bmal1^Mye−/−^;Pkm2^Mye−/−^* mice. Biochemical measurement of circulating levels of tissue injury enzymes also revealed protective effects of *Pkm2* depletion against dysfunction or injury of the heart (creatine kinase \[CK\]), kidney (blood urea nitrogen \[BUN\]), and liver (alanine aminotransferase \[ALT\]) in septic *Bmal1^Mye−/−^;Pkm2^Mye−/−^* mice ([Figure 3F](#F3){ref-type="fig"}). The absence of *Pkm2* significantly inhibited glycolysis (as measured by extracellular acidification rate \[ECAR\]) and increased oxidative phosphorylation (as measured by oxygen consumption rate \[OCR\]) in PMs from septic *Pkm2^Mye−/−^* or *Bmal1^Mye−/−^;Pkm2^Mye−/−^* mice compared to *Bmal1^Mye−/−^* mice ([Figure 3G](#F3){ref-type="fig"}). These findings support the notion that overcoming PKM2-dependent aerobic glycolysis (the Warburg effect) in macrophages may lead to better outcomes in experimental sepsis ([@R16]; [@R48]; [@R50]; [@R51]).

To further test the hypothesis that BMAL1 limits PD-L1 expression in a PKM2-dependent manner, we examined the effects of BMAL1 and PKM2 on the LPS- and HMGB1-induced glycolysis and PD-L1 expression in BMDMs. The levels of lactate production and *Pd-l1* mRNA expression were increased in *Bmal1^Mye−/−^*, but not in *Pkm2^Mye−/−^* or *Bmal1^Mye−/−^;Pkm2^Mye−/−^* BMDMs in response to LPS or HMGB1 ([Figure 3H](#F3){ref-type="fig"}). LPS- or HMGB1-induced lactate production was also not inhibited in macrophages expressing the BMAL I317D mutant ([Figure 3I](#F3){ref-type="fig"}) in *Bmal1^Mye−/−^* BMDMs, indicating that CLOCK-BMAL1 transcriptional activator complex is required for the control of lactate production. *Pkm2^Mye−/−^* mice were less susceptible to the LPS-induced mortality at ZT0 versus ZT12 compared to *Bmal1^Mye−/−^* or *Bmal1^Mye−/−^;Pkm2^Mye−/−^* mice ([Figure 3J](#F3){ref-type="fig"}). These findings further support the idea that BMAL1 plays an important role in gating LPS-induced mortality under circadian control.

PKM2 Is Required for STAT1-Dependent PD-L1 Upregulation {#S6}
-------------------------------------------------------

Like the BMAL1/CLOCK target genes that usually carry an E-box DNA motif on their promoters, bioinformatics analysis also revealed the presence of a classical E-box DNA motif ('CAGCTG') in the promoter region of *Pkm2*, but not *Pd-l1* gene ([Table S1](#SD1){ref-type="supplementary-material"}). Chromatin immunoprecipitation (ChIP) analysis confirmed that BMAL1 could bind directly to the promoter of *Pkm2*, but not *Pd-l1* gene, in LPS-stimulated BMDMs ([Figure 4A](#F4){ref-type="fig"}). Moreover, the depletion of *Bmal1* increased LPS-induced PKM2 expression in BMDMs ([Figure 4B](#F4){ref-type="fig"}), suggesting that BMAL1 inhibits glycolysis by directly repressing the expression of PKM2 in activated BMDMs.

Although PKM2 might be required for the LPS-induced PD-L1 expression in macrophages through a hypoxia-inducible factor 1α (HIF1α)-dependent mechanism ([@R29]), we did not observe a significant change in the LPS-induced HIF1α protein expression ([Figure 4B](#F4){ref-type="fig"}) or its interaction with PKM2 ([Figure 4C](#F4){ref-type="fig"}) in *Bmal1^Mye−/−^* BMDMs compared to control cells. In contrast, the depletion of *Bmal1* led to an elevation of the LPS-induced phosphorylation of STAT1 (a core transactional factor for *Pd-l1* expression; [Figure 4B](#F4){ref-type="fig"}) and PKM2-STAT1 interaction ([Figure 4C](#F4){ref-type="fig"}). Consistently, the LPS-induced STAT1 phosphorylation was impaired in *Bmal1^Mye−/−^*;*Pkm2^Mye−/−^* BMDMs ([Figure 4D](#F4){ref-type="fig"}). The binding of PKM2 and STAT1 (but not HIF1α) to *Pd-l1* promoter were increased in *Bmal1^Mye−/−^* BMDMs, but not in *Bmal1^Mye−/−^;Pkm2^Mye−/−^* BMDMs ([Figure 4E](#F4){ref-type="fig"}). Similar to the depletion of *Pkm2* ([Figure 3H](#F3){ref-type="fig"}), the knockdown of *Stat1* (but not *Hif1*α) reduced LPS-induced *Pd-l1* expression in *Bmal1*-deficient BMDMs ([Figure 4F](#F4){ref-type="fig"}). Like *Bmal1^Mye−/−^* BMDMs, knockdown of *Bmal1* by shRNA exhibited similar effects on LPS-induced PKM2, PD-L1, and p-STAT1 expression in BMDMs ([Figure 4G](#F4){ref-type="fig"}). These findings indicate that PKM2 is a transcriptional coactivator of STAT1 responsible for promoting *Pd-l1* expression in *Bmal1*-deficient BMDMs.

To further define the role of lactate in the regulation of PD-L1 expression, we directly stimulated macrophage and monocyte cell cultures with lactate. Exogenously supplemented lactate induced *Pd-l1* mRNA expression in BMDM and THP1 cells ([Figure 4H](#F4){ref-type="fig"}). Furthermore, the knockdown of G-protein-coupled receptor 81 (*Gpr81*, a lactate receptor) or *Stat1* by shRNA inhibited the lactate-induced STAT1 phosphorylation and PD-L1 protein expression in BMDMs ([Figure 4I](#F4){ref-type="fig"}), supporting that the STAT1 pathway is required for lactate-induced PD-L1 expression in macrophages.

PD-L1 Pathway Contributes to Septic Death in *Bmal1^Mye−/−^* Mice {#S7}
-----------------------------------------------------------------

To determine whether the PD-L1 pathway is responsible for the increase in sepsis lethality in *Bmal1^Mye−/−^* mice, we treated mice with anti-PD-L1 neutralizing antibody. Compared to the administration of control immunoglobulin G (IgG), anti-PD-L1 neutralizing antibody prolonged animal survival in CLP-induced sepsis in *Bmal1^Mye−/−^* mice ([Figure 5A](#F5){ref-type="fig"}). This was also associated with reduced injury in the lung and small intestine ([Figure 5B](#F5){ref-type="fig"}). Lung from septic mice exhibited hemorrhage, leukocyte infiltration, alveolar septal thickening, and edema, whereas intestines displayed markers of injury characterized by the loss of mucosal villi ([Figure 5B](#F5){ref-type="fig"}). These CLP-induced histological changes were attenuated by anti-PD-L1 neutralizing antibody administration in septic *Bmal1^Mye−/−^* mice ([Figure 5B](#F5){ref-type="fig"}). Biochemical measurement of circulating tissue enzymes (CK, BUN, and ALT) also confirmed the protective effects of anti-PD-L1 neutralizing antibody against organ dysfunction and injury ([Figure 5C](#F5){ref-type="fig"}).

We next investigated the impact of PD-L1 blockage on bacterial loads and T cell apoptosis. The administration of anti-PD-L1 neutralizing antibody resulted in a reduction of bacterial loads in the blood and peritoneal lavage fluid ([Figure 5D](#F5){ref-type="fig"}) and an inhibition of caspase 3 activity (an indicator of apoptosis) in splenic CD4+ and CD8+T cells ([Figure 5E](#F5){ref-type="fig"}). Consistently, increased cleaved-caspase 3 protein in splenic CD4+ and CD8+T cells from septic *Bmal1^Mye−/−^* mice were blocked by anti-PD-L1 neutralizing antibody ([Figure 5F](#F5){ref-type="fig"}), supporting a role of PD-L1 in the regulation of lymphocyte survival. In contrast, serum levels of IL-7, a potent anti-apoptotic cytokine for lymphocyte proliferation, were increased in septic *Bmal1^Mye−/−^* mice following anti-PD-L1 neutralizing antibody treatment ([Figure 5G](#F5){ref-type="fig"}). The administration of recombinant IL-7 also increased animal survival ([Figure 5A](#F5){ref-type="fig"}) and reversed disease phenotype ([Figures 5C](#F5){ref-type="fig"}--[5F](#F5){ref-type="fig"}) in septic *Bmal1^Mye−/−^* mice. Thus, inhibition of PD-L1 or administration of IL-7 protects mice from sepsis-induced lethality and displays reduced organ damage, improved bacterial clearance, and increased T cell survival.

DISCUSSION {#S8}
==========

Sepsis is the leading cause of death in intensive care units and recognized as a global health priority by the current World Health Organization ([@R32]). In the present study, we demonstrate that circadian clock controls the immune checkpoint pathway in sepsis. In macrophages, BMAL1-mediated circadian oscillations are required for lactate metabolism, which controls PD-L1 expression to affect T cell survival in sepsis. Genetic depletion of *Bmal1* increased the risk of septic death, whereas anti-PD-L1 antibody rendered mice more resistant to polymicrobial sepsis. These findings not only provide insights into the molecular function of the circadian clock gene in immunity but also reinforce the notion that targeting immune checkpoints have potential for treating infectious diseases that lead to lethal sepsis ([@R18]).

Abnormal circadian rhythms have been associated with various pathological conditions, inducing lethal inflammation and immune dysfunction. Disruption of the molecular clock in mice via genetic ablation of the myeloid *Baml1* gene or artificially mimicking jet lag increases the acute inflammatory response during endotoxemia ([@R5]; [@R8]; [@R10]; [@R11]). Accordingly, proinflammatory cytokines (e.g., IL-6, IL-12, and tumor necrosis factor) and chemokines (e.g., C-X-C motif chemokine ligand 1, C-C motif chemokine ligand 5, and C-C motif chemokine ligand 2 \[CCL2\]) were excessively induced by endotoxemia in animals with abnormal circadian rhythms ([@R5]; [@R8]; [@R10]; [@R11]; [@R13]; [@R21]; [@R23]; [@R24]). Mechanistically, circadian control of the innate inflammatory response involves the regulation of Toll-like receptor expression ([@R36]), nuclear factor κB (NF-κB) activation ([@R39]), miR-155 induction ([@R8]), and epigenomic states of enhancers ([@R26]). Depletion of the clock component *Nr1d1/Rev-erb*α (a transcriptional repressor of BMAL1) in mice exhibits a loss of a gated inflammatory response (especially IL-6 production) to LPS ([@R11]). Moreover, *Nr1d1/Rev-erba*α is a direct transcriptional repressor of the *Ccl2* in activated macrophages ([@R33]), supporting that the circadian clock plays a crucial role in the regulation of the inflammation response.

Our present study has suggested the involvement of BMAL1 in the control of immune checkpoint protein PD-L1 expression during polymicrobial sepsis. We observed an increase in CLP-induced lethality in *Bmal1^Mye−/−^* mice, which was associated with elevated lactate production and PD-L1 expression, highlighting a potential role of lactate as an immunosuppressor that contributes to sepsis development and severity. Indeed, lactic acidosis has been suggested as an independent predictor of sepsis mortality ([@R43]). We also observed that LPS and HMGB1 promote lactate production in macrophages through PKM2-dependent glycolysis. Consequently, conditional depletion of *Pkm2* in myeloid cells prevented the enhanced sepsis phenotype and reduced animal survival observed in *Bmal1^Mye−/−^* mice, supporting the pathologic role of metabolic reprogramming in sepsis. The impact of the circadian clock on the regulation of glycolysis may depend on tissue type. For example, *Bmal1^−/−^* skeletal muscle exhibits impaired glycolysis due to reduced HIF1α expression under hypoxia ([@R31]). Our current data indicate that LPS-induced HIF1α expression in macrophages is not affected by BMAL1. The loss of *Cry1/2* also does not affect hypoxia-induced HIF1α expression ([@R31]). Thus, these circadian clock genes may not share a common mechanism in the regulation of HIF1α expression in different stresses or cells.

Glycolysis metabolites, including lactate, have emerged as critical regulators of the inflammation and the immune response ([@R25]). Besides its role in the regulation of inflammasome activation ([@R48]) and T cell function ([@R12]), we observed that lactate induced PD-L1 expression in macrophages in a GPR81-dependent manner. GPR81 acts as a cell-surface receptor for lactate and promotes the expression of PD-L1 by activation of STAT1, a transcription factor in interferon-dependent responses. Our data suggested that PKM2, but not PD-L1, is a transcriptional target of BMAL1 in macrophages. PKM2 upregulation by *Bmal1* deficiency is required for lactate production and STAT1-mediated PD-L1 expression in macrophages. Our findings are broadly consistent with recent findings that PKM2 regulates PD-L1 expression in tumor cells and immune cells ([@R29]). Our study also suggests a specific role for PKM2-mediated transcription and upregulation of PD-L1 in *Bmal1^−/−^* macrophages following LPS treatment. Of note, bone marrow cells from *Bmal1^−/−^* mice exhibit downregulation of PD-L1 expression during *Mycobacterium tuberculosis* infection ([@R41]). The context-dependent activity and cofactor of BMAL1 in the regulation of PD-L1 expression remains to be further explored.

Sepsis and cancer share many immunosuppressive mechanisms, including the increased expression of PD-1 and PD-L1 with T cell exhaustion ([@R14]). PD-1 and its ligand, PD-L1, are increasingly recognized as powerful targets to enhance tumor-directed cytotoxic T cell function ([@R6]). We observed that the loss of *Bmal1* increased PD-L1 expression in macrophages. Importantly, anti-PD-L1 neutralizing antibodies improved septic survival, reduced lymphocyte apoptosis, and improved bacterial clearance in *Bmal1^Mye−/−^* mice. IL-7 is a promising immunotherapeutic agent that reverses immunosuppression and improves survival in septic animals and patients through enhancing T cell viability and function ([@R44]; [@R46]). Our study indicates that supplementation with IL-7 or administration of anti-PD-L1 neutralizing antibodies may ameliorate the sepsis-induced loss of immune effector CD4 and CD8 T cells in the spleen as well as organ dysfunction and injury in *Bmal1^Mye−/−^* mice. We would anticipate that IL-7 and immune checkpoint inhibition have differing functions in reversing sepsis-induced immunosuppression ([@R34]). Therefore, the recent successes of several immunomodulatory agents in cancer could provide hope for and insight into potential immunostimulatory therapies in sepsis as well ([@R30]; [@R35]).

In summary, we have uncovered an essential role of the core clock gene *Bmal1* in protecting against lethal sepsis through regulating macrophage-metabolism-associated PD-L1 expression and T cell apoptotic cell death. Further studies will be aimed at defining the molecular and cellular mechanisms within immune cells implicated in circadian responses, possibly offering opportunities to design immunotherapeutic strategies for sepsis.

EXPERIMENTAL PROCEDURES {#S9}
=======================

Reagents {#S10}
--------

The antibodies to BMAL1 (no. 14020), CLOCK (no. 5157), TIM-3 (no. 83882), PKM2 (no. 4053), cleaved caspase-3 (no. 9661), STAT1 (no. 14994), phospho-STAT1 (Tyr701; no. 9167), and actin (no. 3700) were obtained from Cell Signaling Technology. The antibody to GPR81 (no. orb335576) was obtained from Biorbyt. The antibodies to HIF-1α (no. ab2185) and BMAL1 (no. ab3350) were obtained from Abcam. The antibody to PD-L1 (no. MAB90781), PD-L2 (no. AF1022), and CTLA-4 (no. AF476) were obtained from R&D Systems. LPS (*Escherichia coli* LPS 0111:B4; no. L4391) and lactate (no. L6661) were obtained from Sigma. Recombinant mouse IL-7 (no. 577808), recombinant mouse HMGB1 (no. 764006), recombinant human HMGB1 (no. 557804), and anti-mouse PD-L1 neutralizing antibody (no. 124329) were obtained from BioLegend.

Cell Culture {#S11}
------------

THP1 cells (no. TIB-202) were obtained from American Type Culture Collection. BMDMs were obtained using L929-cell-conditioned medium as a source of granulocyte or macrophage colony stimulating factor. Mouse PMs (peritoneal exudate cells) were isolated from mice as previously described ([@R1]). Mouse neutrophil was isolated from circulating blood using the Neutrophil Isolation Kit (no. 130-097-658; Miltenyi Biotec). These cells were cultured in DMEM (supplemented with 10% heat-inactivated fetal bovine serum and 100 units of penicillin and 100 mg/mL streptomycin) at 37°C, 95% humidity, and 5% CO~2~. All cells were mycoplasma free and authenticated by Short Tandem Repeat DNA Profiling Analysis.

Animal Model of Sepsis {#S12}
----------------------

We conducted all animal care and experiments in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care guidelines (<https://www.aaalac.org>) and with approval from our Institutional Animal Care and Use Committee.

*LysM-Cre* (no. 004781), *Bmal1* ^*flox/flox*^ (no. 007668), and *Pkm2* ^*flox/flox*^ (no. 024048) mice were purchased from The Jackson Laboratory. These mice were used to generate myeloid-cell-specific *Bmal1*-knockout, *Pkm2*-knockout, or double-knockout mice. Mice were housed under a regular 12 hr light and dark cycle (7:00--19:00 light period) at a constant temperature of 22°C ± 1°C and relative humidity of 40%--60%. During this period, food and water were available *ad libitum*. All animal experiments, including surgical procedures and sample harvests, were carried out under pathogen-free conditions.

Polymicrobial sepsis was induced in C57BL/6J mice (8--10 weeks old; 22--26 g; half male:halffemale) at ZT0--3 (except for [Figure 1G](#F1){ref-type="fig"}) using a surgical procedure as previously described ([@R19]). Briefly, anesthesia was induced with ketamine and xylazine. A small midline abdominal incision was made and the cecum was exteriorized and ligated with 4--0 silk immediately distal to the ileocecal valve without causing intestinal obstruction. The cecum was then punctured twice with a 17G--27G needle. The abdomen was closed in two layers, and mice were injected subcutaneously with 1 mL Ringer's solution including analgesia (0.05 mg/kg buprenorphine).

Endotoxemia model: LPS (*Escherichia coli 0111:B4*; no. L4391; Sigma) was dissolved in PBS. C57BL/6J mice (8--10 weeks old; 22--26 g; half male:half female) received LPS at 15 mg/kg intraperitoneally (i.p.).

Biochemical Assay {#S13}
-----------------

Lactate in culture medium or serum was measured with the L-Lactate Assay Kit (Abcam; no. ab65331). Activation of caspase-3 in cell lysates was measured with the caspase-3 Assay Kit (Abcam; no. ab39401). Neutrophil activity was measured with the Myeloperoxidase Activity Assay Kit (Abcam; no. ab105136). Activation of tissue enzymes (CK, BUN, and ALT) in serum was performed using the IDEXX Catalyst Dx Chemistry Analyzer (IDEXX Laboratories).

RNAi and Gene Transfection {#S14}
--------------------------

Human *Bmal1*-shRNA-1 (sequence: 5'-`CCGGCTTCTAGGCACATCGTGTTATCTCGAGATAACACGATGTGCCTAGAAGTTTTTG`-3'); human *Bmal1*-shRNA-2 (sequence: 5'-`CCGGGCAGAATGTCATAGGCAAGTTCTCGAGAACTTGCCTATGACATTCTGCTTTTT`-3'), human *Clock*-shRNA-1 (sequence: 5'-`CCGGCGCACACATAGGCCATCTTATCTCGAGATAAGATGGCCTATGTGTGCGTTTTT`-3'); human *Clock*-shRNA-2 (sequence: 5'-`CCGGCGACGAGAACTTGGCATTGAACTCGAGTTCAATGCCAAGTTCTCGTCGTTTTT`-3'), mouse *Bmal1*-shRNA (sequence:5'-`CCGGACATAGGCATCGATATGATAGCTCGAGCTATCATATCGATGCCTATGTTTTTTG`-3'), mouse *Grp81*-shRNA (sequence: 5'-`CCGGCCTGGAAGTCAAGCACTATTTCTCGAGAAATAGTGCTTGACTTCCAGGTTTTT`-3'), and mouse *Stat1*-shRNA (sequence: 5'-`CCGGGCTGTTACTTTCCCAGATATTCTCGAGAATATCTGGGAAAGTAACAGCTTTTTG`-3') were obtained from Sigma. Bmal1-wild-type and Bmal1-I317D mutant were a gift from Joseph Takahashi. Transfection was performed using lentiviral vector or Lipofectamine 3000 (no. L3000--015; Invitrogen). Puromycin (no. ant-pr-1; InvivoGen) was used to generate stable knockdown cell lines.

Western Blot Analysis {#S15}
---------------------

Western blot was used to analyze protein expression as described previously ([@R40]; [@R42]; [@R49]). In brief, after extraction, proteins in cell lysates were first resolved by 4%--12% Criterion XT Bis-Tris gels (Bio-Rad; no. 3450124) in XT MES running buffer (Bio-Rad; no. 1610789) and then transferred to polyvinylidene difluoride membrane (pore size 0.22 μM; Bio-Rad; no. 1620233). The membranes were blocked with Tris-buffered saline Tween 20 containing 5% skim milk for 1 hr at room temperature and then incubated with the indicated primary antibodies (1:500--1:2,000) overnight at 4°C. After incubation with peroxidase-conjugated secondary antibodies (1:2,000--1:4,000), the signals were visualized by enhanced chemiluminescence (no. 32106; Pierce).

qPCR {#S16}
----

Total RNA was extracted using QIAGEN RNeasy Plus Kit. First-strand cDNA was synthesized from 1 μg of RNA using the iScript cDNA Synthesis kit (no. 1708890; Bio-Rad). Briefly, 20 μL reactions were prepared by combining 4 μL iScript Select reaction mix, 2 μL gene-specific enhancer solution, 1 mL reverse transcriptase, 1 μL gene-specific assay pool (20×; 2 μM), and 12 μL RNA diluted in RNase-free water. Real-time qPCR was carried out using synthesized cDNA, primers, and SsoFast EvaGreen Supermix (no. 172--5204; BioRad). The expression of target genes was calculated using the ddCt method relative to the expression of a house-keeping gene, β-actin ([@R37]; [@R52]). Data shown are the relative quantity (RQ), with RQ of the control cells set to one. The specific primers were listed as below: mouse *Bmal1*: 5'-`ACCTCGCAGAATGTCACAGGCA`-3' and 5'- `CTGAACCATCGACTTCGTAGCG`-3'; mouse *Per1*: 5'- `GAAACCTCTGGCTGTTCCTACC`-3' and 5'- `AGGCTGAAGAGGCAGTGTAGGA`-3'; mouse *Per2*: 5'- `CTGCTTGTTCCAGGCTGTGGAT`-3' and 5'- `CTTCTTGTGGATGGCGAGCATC`-3'; mouse *Per3*: 5'- `CACAGACATCGAAGGAGGTGCT`-3' and 5'-`CTTACACGCCACGGCAACACTT`-3'; human *Pd-l1*: 5'- `TGCCGACTACAAGCGAATTACTG`-3' and 5'- `CTGCTTGTCCAGATGACTTCGG`-3'; mouse *Pd-l1*: 5'- `TGCGGACTACAAGCGAATCACG`-3' and 5'- `CTCAGCTTCTGGATAACCCTCG`-3'; mouse *Pd-l2*: 5'- `CTGGGACTACAAGTACCTGACG`-3' and 5'- `CTCTAGCCTGGCAGGTAAGCTG`-3'; mouse *Ctla-4*: 5'- `GTACCTCTGCAAGGTGGAACTC`-3' and 5'- `CCAAAGGAGGAAGTCAGAATCCG`-3'; mouse *Tim-3*: 5'-`ACAGACACTGGTGACCCTCCAT`-3' and 5'- `CAGCAGAGACTCCCACTCCAAT`-3'; mouse *β-actin*: 5'-`CTGTCCCTGTATGCCTCTG`-3' and 5'-`ATGTCACGCACGATTTCC`-3'; and human *β-actin*: 5'-`AGCGAG CATCCCCCAAAGTT`-3' and 5'-`AGGGCA CGAAGGCTCATCATT`-3'.

Oxidative Phosphorylation and Glycolysis Assay {#S17}
----------------------------------------------

Cellular OXPHOS and glycolysis were monitored using the Seahorse Bioscience Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA) by measuring basal OCR (indicative of respiration) and ECAR (indicative of glycolysis) as previously described ([@R50]).

ChIP {#S18}
----

ChIP assay was performed using the Pierce ChIP Kit (no. 26156; Thermo Scientific). One-twentieth of the immunoprecipitated DNA was used in qPCR. Results were shown as percentage of input. BMAL1, STAT1, PKM2, and HIF1α antibodies used for ChIP were acquired from Cell Signaling Technology or Abcam. The following primers were used for qPCR of DNA quantification: *Pd-l1* promoter: 5'-`CACTGGCTCCTGAGTACTGG`-3' and 5'-`CTGTCTGTGAAACCGAAGCC`-3'; *Pkm2* promoter: 5'-`TGGTCTACGATGTCCTTCCG`-3' and 5'-`TGAGAGAAGCTCAGGGTAGG`-3'.

Histologic Examination {#S19}
----------------------

After fixation in 4% phosphate-buffered formaldehyde, tissues were embedded in optimum cutting temperature cryomedium (Sakura Finetek) and cut into 4-μm sections. H&E (modified Harris Hematoxylin, Thermo Scientific; Eosin-Y, Thermo Scientific) staining was performed for each section to examine histomorphologic features ([@R19]). All histologic examinations were performed by a pathologist who specializes in the pathophysiology of sepsis. Lung and intestine injury was evaluated and scored according to previous criterions ([@R22]; [@R27]).

CD4+ and CD8+ T Cell Isolation {#S20}
------------------------------

A single-cell suspension from mouse spleen was prepared using gentleMACS Dissociator (no. 130-093-235; Miltenyi Biotec). CD4+ and CD8+ T cells were then isolated from this single-cell suspension using the magnetic CD4+ T Cell Isolation Kit (no. 130-104-454; Miltenyi Biotec) or CD8+ T Cell Isolation Kit (no. 130-104-075; Miltenyi Biotec) according to the manufacturer's instructions.

Measurement of Bacterial Counts {#S21}
-------------------------------

The peritoneal cavity was washed with 1 mL PBS, and the peritoneal lavage was collected under sterile conditions. Samples of blood and peritoneal lavage fluid were serially 10-fold diluted in sterile saline and cultured on tryptic soy agar pour plates (Becton Dickinson; no. BA-256665.02). Plates were incubated (37°C) for 24--48 hr, and colony counts were performed ([@R19]).

Statistical Analysis {#S22}
--------------------

Unpaired Student's t tests were used to compare the means of two groups. One-way ANOVA was used for comparison among the different groups. When ANOVA was significant, post hoc testing of differences between groups was performed using the least significant difference (LSD) test. The Kaplan-Meier method was used to compare differences in mortality rates between groups. A p value \< 0.05 was considered statistically significant. In all experiments, animals were randomized to different treatment groups without blinding. Sample size in experiments was specified in each figure legend. We did not exclude samples or animals. For every figure, statistical tests are justified as appropriate. All data meet the assumptions of the tests. No statistical methods were used to pre-determine sample sizes, but our sample sizes are similar to those generally employed in the field. SigmaPlot 11.0 was used to analyze the data.
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![Altered Circadian and Sepsis Phenotype in *Bmal1^Mye−/−^* Mice\
(A) Western blot analysis of BMAL1 expression in PMs, livers, and brains from *Bmal1* ^*flox/flox*^ and *Bmal1^Mye−/−^* mice.\
(B) Ablation of Bmal1 in the myeloid cells results in disrupted circadian expression of clock genes Bmal1, Per1, Per2, and Per3 in PMs (n = 3 mice/group; data expressed as means ± SD).\
(C) Ablation of Bmal1 in myeloid cells does not disrupt circadian expression of clock genes Bmal1, Per1, Per2, and Per3 in liver (n = 3 mice/group; data expressed as means ± SD)\
(D−F) Indicated mice were subjected to CLP during ZT0--4 with syringe needles with gauges ranging from 27G (D; 'low-grade sepsis'), 22G (E; 'middle-grade sepsis'), to 17G (F; 'high-grade sepsis'). Animal survival was assayed (n = 12--20 mice/group; \*p \< 0.05; Kaplan-Meier survival analysis).\
(G) Indicated mice were subjected to CLP-induced middle-grade sepsis at ZT0 or ZT12. Animal survival was assayed (n = 8--12 mice/group; \*p \< 0.05; Kaplan-Meier survival analysis).](nihms-1500938-f0002){#F1}

![The Circadian Clock Limits PD-L1 Expression in Activated Macrophages and Monocytes\
(A) qPCR analysis of expression of indicated genes in PMs from middle-grade septic *Bmal1* ^*flox/flox*^ and *Bmal1^Mye−/−^* mice (n = 3 mice/group; data expressed as means ± SD; \*p \< 0.05; ANOVA LSD test).\
(B) Western blot analysis of expression of indicated proteins in PMs at day 3 from middle-grade septic *Bmal1 ^flox/flox^* and *Bmal1^Mye−/−^* mice (n = 3 mice/group).\
(C) qPCR analysis of *Pd-l1* and *Pd-l2* mRNA expression in indicated BMDMs treated with LPS (100 ng/mL) or HMGB1 (500 ng/mL) for 24--48 hr (n = 3; data expressed as means ± SD; \*p \< 0.05; t test).\
(D) Western blot analysis of PD-L1 and PD-L2 protein expression in indicated BMDMs treated with LPS (100 ng/mL) or HMGB1 (500 ng/mL) for 48 hr.\
(E) Western blot analysis of BMAL or CLOCK protein expression in indicated knockdown THP1 cells.\
(F) Knockdown of *Bmal1* or *Clock* increased LPS (100 ng/mL)- or HMGB1 (500 ng/mL)-induced *Pd-l1* mRNA expression in THP1 cells (n = 3; data expressed as means ± SD; \*p \< 0.05; t test).\
(G) Bmal1 wild-type, but not I317D mutant, restored the inhibition of LPS (100 ng/mL)- or HMGB1 (500 ng/mL)-induced *Pd-l1* mRNA expression in *Bmal1^Mye−/−^* BMDMs (n = 3; data expressed as means ± SD; \*p \< 0.05; t test).\
(H) Wild-type PMs were harvested at ZT0 and ZT12 and treated immediately with LPS (100 ng/mL) for 24 hr and analyzed for *Pd-l1* mRNA expression (n = 3; data expressed as means ± SD; \*p \< 0.05; t test).\
(I) Indicated neutrophils harvested from middle-grade septic *Bmal1 ^flox/flox^* and *Bmal1^Mye−/−^* mice were exposed to phorbol 12-myristate 13-acetate (PMA; 0.08 μM) for 30 min and analyzed for myeloperoxidase (MPO) release (n = 3; data expressed as means ± SD).](nihms-1500938-f0003){#F2}

![BMAL1 Limits PD-L1 Expression in a Lactate-Metabolism-Dependent Manner\
(A) Western blot analysis of BMAL1 and PKM2 protein expression in indicated PMs.\
(B) qPCR analysis of *Bmal1*, *Per1*, and *Per2* mRNAs in indicated PMs (n = 3 mice/group; data expressed as means ± SD).\
(C) Indicated mice were subjected to CLP with 22G syringe needles (middle-grade sepsis), and animal survival was assayed (n = 20 mice/group; \*p \< 0.05; Kaplan-Meier survival analysis).\
(D--F) Analysis of serum lactate (D), *Pd-l1* mRNA in PMs (E), and serum tissue function enzyme (F) in indicated middle-grade septic mice (n = 3 mice/group; data expressed as means ± SD).\
(G) Basal ECAR (indicative of glycolysis) and OCR (indicative of oxidative phosphorylation) were monitored at isolated PMs from indicated CLP (72 hr)-induced septic mice (n = 3 mice/group; \*p \< 0.05 versus *Bmal1^Mye−/−^* group; data expressed as means ± SD).\
(H) Analysis of lactate production and *Pd-l1* mRNA in indicated BMDMs following treatment with LPS (100 ng/mL) or HMGB1 (500 ng/mL) for 48 hr (n = 3; data expressed as means ± SD; \*p \< 0.05; ANOVA LSD test).\
(I) Bmal1 wild-type, but not I317D mutant, restored the inhibition of LPS (100 ng/mL)- or HMGB1 (500 ng/mL)-induced lactate production in *Bmal1^Mye−/−^* BMDMs (n = 3; data expressed as means ± SD; \*p \< 0.05; ANOVA LSD test).\
(J) Indicated mice were subjected to LPS (15 mg/kg)-induced endotoxemia at ZT0 or ZT12. Animal survival was assayed (n = 10 mice/group; \*p \< 0.05; Kaplan-Meier survival analysis).\
\*p \< 0.05.](nihms-1500938-f0004){#F3}

![BMAL1-Mediated PKM2 Expression Contributes to STAT1-Dependent PD-L1 Upregulation\
(A) Binding of BMAL1 to *Pd-l1* or *Pkm2* promoter was analyzed by ChIP-qPCR in BMDMs following treatment with LPS (100 ng/mL) for 48 hr (n = 3; data expressed as means ± SD; \*p \< 0.05; t test).\
(B) Western blot analysis of indicated proteins in BMDMs following treatment with LPS (100 ng/mL) for 48 hr.\
(C) Immunoprecipitation analysis of indicated protein complexes in BMDMs following treatment with LPS (100 ng/mL) for 48 hr.\
(D) Western blot analysis of indicated proteins in BMDMs following treatment with LPS (100 ng/mL) for 48 hr.\
(E) Binding of PKM2, STAT1, or HIF1α to *Pd-l1* promoter was analyzed using ChIP-qPCR in indicated BMDMs following treatment with LPS (100 ng/mL) for 48 hr (n = 3; data expressed as means ± SD; \*p \< 0.05; t test).\
(F) qPCR analysis of *Pd-l1* mRNA in indicated BMDMs following treatment with LPS (100 ng/mL) for 48 hr (n = 3; data expressed as means ± SD; \*p \< 0.05; t test).\
(G) Western blot analysis of expression of indicated proteins in BMDMs following treatment with LPS (100 ng/mL) for 48 hr.\
(H) qPCR analysis of *Pd-l1* mRNA in BMDMs and THP1 cells following treatment with lactate (10 mM) for 12--48 hr (n = 3; data expressed as means ± SD; \*p \< 0.05 versus untreated group; t test).\
(I) Knockdown of STAT1 and GPR81 inhibited lactate (10 mM; 24 hr)-induced PD-L1 protein expression in BMDMs (n = 3; data expressed as means ± SD; \*p \< 0.05 versus control shRNA group; t test).\
See also [Table S1](#SD1){ref-type="supplementary-material"}.](nihms-1500938-f0005){#F4}

![The PD-L1 Pathway Contributes to Septic Death in *Bmal1^Mye−/−^* Mice\
(A) Repeated administration of anti-PD-L1 antibody (20 mg/kg) or IL-7 (5 mg/mice) at 3, 24, 48, and 72 hr after CLP (22G needle) significantly increased survival in indicated mice (n = 20 mice/group; \*p \< 0.05; Kaplan-Meier survival analysis).\
(B--G) In parallel, tissue H&E staining and injury score (day 3; scale bars, 200 αM; B), serum enzyme activity (C), bacterial loading (D), and caspase 3 activity in T cells (E) were assayed (n = 3--5 mice/group; data expressed as means ± SD; \*p \< 0.05; ANOVA LSD test).\
(F) Western blot analysis of cleaved-caspase 3 in indicated T cells.\
(G) Serum levels of IL-7 in indicated septic mice (n = 3 mice/group; data expressed as means ± SD; \*p \< 0.05; ANOVA LSD test).](nihms-1500938-f0006){#F5}

###### Highlights

-   *Bmal1* deficiency in myeloid cells increases polymicrobial infection in mice

-   The circadian clock blocks PD-L1 expression in activated macrophages and monocytes

-   PKM2 is required for STAT1-dependent PD-L1 upregulation

-   PD-L1 pathway contributes to septic death in *Bmal^Mye−/−^* mice
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